It's notable that the FDA label expansion for the G5 monitor three weeks ago did nothing for the stock price (#msg-127319780), but the new CMS classification—which is what drives reimbursement—caused a big move.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”